ABOUT DIAMYD MEDICAL
ABOUT DIAMYD MEDICAL
The Diamyd Story
CEO Comments
Board & Management
Scientific Advisory Board
Corporate Governance
Annual General Meeting
Board & Management
Auditors
Articles of Incorporation
Remuneration Principles
Incentive Programs
Partnering
Contact Us
DIABETES
DIABETES
Type 1
LADA
Type 2
Complications
PRODUCTS & PIPELINE
PRODUCTS & PIPELINE
GAD platform
Diamyd
®
Diamyd
®
in Type 1
Diamyd
®
in LADA
Order GAD for research
CLINICAL TRIALS
CLINICAL TRIALS
Clinical development
Diabetes Clinical Trials
Drug Development
INVESTOR RELATIONS
INVESTOR RELATIONS
Press Releases
Financial Reports
Calendar
Owners
Share Trading
Insider Trading
Company Description
Shares Issue
PRESS ROOM
PRESS ROOM
Press Releases
News & Mediawatch
Scientific publications
Webcasts/Podcasts
Newsletter Subscription
Media Contact
This website is only intended for investors
Fighting diabetes
Diamyd Medical is a diabetes company active in the field of pharmaceutical development. The Company is headquartered in Stockholm, Sweden and shares are listed on NASDAQ OMX First North (ticker: DMYD B).
The new Diamyd will be a dedicated diabetes company with an initial focus on the development of the diabetes vaccine Diamyd
®
Diabetes − a chronic disease
Diabetes is associated with serious complications due to elevated and fluctuating blood sugar levels, causing substantial suffering and extensive costs for society.
CEO Comments
The listing of the new Diamyd Medical AB on First North marks the start of a new, exciting chapter for our diabetes operation. The new Diamyd is a dedicated diabetes company with an initial focus on the diabetes...
Diamyd
®
− The Diabetes Vaccine
Diamyd
®
is a GAD-based therapy under development for the treatment and prevention of autoimmune diabetes such as type 1 diabetes and LADA. Treatment with Diamyd
®
aims to intervene in the autoimmune...
Pressmeddelande: Diamyds storägare tecknar fullt ut i företrädesemission
Press Releases
June 13, 2013 08:30 AM
Diamyd expands its Scientific Advisory Board
May 28, 2013 14:26 PM
Diamyd implements rights issue of approximately MSEK 21 to fund expanded diabetes portfolio
May 17, 2013 17:23 PM
Chairman increases holdings in Diamyd
News & Mediawatch
June 19, 2013, Sweden
Lifescience.idg.se: GABA-experter till Diamyd
Nu rekryterar Diamyd Medical tre internationella diabetesforskare till bolagets vetenskapliga och medicinska råd. Samtliga forskare har...
May 21, 2013, Sweden
Diamyd presents at exclusive showcase at BioEquity Europe 2013 in Stockholm:...
The hotlist features carefully selected, investment-ready Stockholm-Uppsala based companies on the cutting edge of life science. Hotlist companies...
May 21, 2013, Sweden
Webcast från Avanza Banks börsdag på Operaterassen i Stockholm
Diamyd Medicals VD Peter Zerhouni presenterar "nya" Diamyd Medical på Avanza Banks börsdag den 21 maj 2013 på Operaterassen i...
May 20, 2013, Sweden
nasdaqomx.com: Nasdaq OMX welcomes Diamyd Medical to First North
NASDAQ OMX announces that the trading in Diamyd Medical AB (short name: DMYD B) shares will commence today on First North at NASDAQ OMX Stockholm....
May 20, 2013, Sweden
SvD.se: Diamyds forskning noteras på börsen
Diamyd Medical illustrerar risken med ett forskningsbolag. I mycket sena kliniska studier visade det sig att den tongivande produkten,...
May 16, 2013, Sweden
di.se: Diamyd reser sig ur askan
Det nya Diamyd Medical, som knoppades av från moderbolaget i april 2013, listas på Nasdaq OMX First North med första handelsdag den...
May 16, 2013, Sweden
Diamyd Medical medverkar på Avanza Banks Börsdag på Operaterrassen i Stockholm
Diamyd Medical är ett av flera bolag som presenterar på Avanza Banks Börsdag den 21 maj 2013. Diamyd Medicals VD Peter Zerhouni...
May 07, 2013, Sweden
hn.se: Diabetesvaccin har hjälpt Louise Gattzén
I dagens upplaga av Hallands Nyheter berättar Louise Gattzén om hur hennes insulinproduktion ligger kvar på samma nivå som...
Financial Reports
No reports published yet.
